






Amendments to the Claims



The following listing of claims will replace all prior versions, and listings, of claims in the application.

1-81. (Canceled)

82. (Currently Amended) A pharmaceutical composition for reducing skin pigmentation, wherein the pharmaceutical composition is an ointment, cream, lotion or emulsion formulated for percutaneous absorption by topical administration, comprising a skin pigmentation reducing effective amount of a compound and a dermatologically-acceptable carrier, wherein the compound is selected from the group consisting of:







pharmaceutically-acceptable salts thereof, and combinations thereof.

83-92. (Canceled)

93. (Previously presented) The pharmaceutical composition of claim 82, further comprising a skin-peeling agent.




94. (Previously presented) The pharmaceutical composition of claim 93, wherein the skin-peeling agent is glycolic acid or trichloroacetic acid.


95. (Previously presented) The pharmaceutical composition of claim 82, further comprising a sunscreen.

96. (Previously presented) The pharmaceutical composition of claim 95, wherein the sunscreen is a UVA blocker or a UVB blocker.


97. (Previously presented) The pharmaceutical composition of claim 82, further comprising retinoic acid.
98. (Previously presented) The pharmaceutical composition of claim 82, further comprising 4-hydroxyanisole.
99. (Previously presented) The pharmaceutical composition of claim 82, further comprising ascorbic acid.
100. (Previously presented) The pharmaceutical composition of claim 82, further comprising magnesium ascorbate.
101. (Previously presented) The pharmaceutical composition of claim 82, further comprising an anti-oxidant.
102. (Previously presented) The pharmaceutical composition of claim 101, wherein the anti-oxidant is resveratrol.
103. (Previously presented) The pharmaceutical composition of claim 82, further comprising a tyrosinase inhibitor.
104. (Previously presented) The pharmaceutical composition of claim 103, wherein the tyrosinase inhibitor is selected from the group consisting of resorcinol, hydroquinone, kojic acid, and melamine.
105. (Previously presented) The pharmaceutical composition of claim 82, further comprising an agent that enhances percutaneous administration selected from the group consisting of dimethylsulfoxide, dimethylacetamide, dimethylformamide, azone, acetone, propylene glycol, and polyethylene glycol.

106. (Previously presented) The pharmaceutical composition of claim 82, wherein the compound is a pharmaceutically-acceptable acid salt of a compound selected from the group consisting of:







(V)



(VI)






(VII)







(VIII)

and combinations thereof.

107. (Previously presented) The pharmaceutical composition of claim 82, wherein the compound is a pharmaceutically-acceptable base salt of a compound selected from the group consisting of:





and combinations thereof.